Show simple item record

dc.creatorMartin, Rosemarie A.
dc.creatorAlexander-Scott, Nicole
dc.creatorBerk, Justin
dc.creatorCarpenter, Ryan W.
dc.creatorKang, Augustine
dc.creatorHoadley, Ariel
dc.creatorKaplowitz, Eliana
dc.creatorHurley, Linda
dc.creatorRich, Josiah D.
dc.creatorClarke, Jennifer G.
dc.date.accessioned2024-03-29T19:09:35Z
dc.date.available2024-03-29T19:09:35Z
dc.date.issued2022-12-23
dc.identifier.citationRosemarie A. Martin, Nicole Alexander-Scott, Justin Berk, Ryan W. Carpenter, Augustine Kang, Ariel Hoadley, Eliana Kaplowitz, Linda Hurley, Josiah D. Rich, Jennifer G. Clarke, Post-incarceration outcomes of a comprehensive statewide correctional MOUD program: a retrospective cohort study, The Lancet Regional Health - Americas, Volume 18, 2023, 100419, ISSN 2667-193X, https://doi.org/10.1016/j.lana.2022.100419.
dc.identifier.issn2667-193X
dc.identifier.urihttp://hdl.handle.net/20.500.12613/10114
dc.description.abstractBackground: As opioid overdoses surge, medications for opioid use disorder (MOUD) remain underutilized. MOUD is rarely offered in correctional facilities although individuals involved in the criminal justice system have higher rates of OUD and mortality relative to the general population. Methods: A retrospective cohort design examined the effect of MOUD while incarcerated on 12 months post-release treatment engagement and retention, overdose mortality, and recidivism. Individuals (N = 1600) who participated in the Rhode Island Department of Corrections (RIDOC) MOUD program (the United States’ first statewide program) and were released from incarceration from December 1, 2016, to December 31, 2018, were included. The sample was 72.6% Male (27.4% female) and 80.8% White (5.8% Black, 11.4% Hispanic, 2.0% another race). Findings: 56% were prescribed methadone, 43% buprenorphine, and 1% naltrexone. During incarceration, 61% were continued on MOUD from the community, 30% were inducted onto MOUD upon incarceration, and 9% were inducted pre-release. At 30 days and 12 months post-release, 73% and 86% of participants engaged in MOUD treatment, respectively, and those newly inducted had lower post-release engagement than those who continued from the community. Reincarceration rates (52%) were similar to the general RIDOC population. Twelve overdose deaths occurred during the 12-month follow-up, with only one overdose death during the first two weeks post-release. Interpretations: Implementing MOUD in correctional facilities, with seamless linkage to community care is a needed life-saving strategy. Funding: Rhode Island General Fund, the NIH of Health HEAL Initiative, the NIGMS, and the NIDA.
dc.format.extent10 pages
dc.languageEnglish
dc.language.isoeng
dc.relation.ispartofFaculty/ Researcher Works
dc.relation.haspartThe Lancet Regional Health. Americas, Vol. 18
dc.relation.isreferencedbyElsevier
dc.rightsAttribution-NonCommercial-NoDerivs CC BY-NC-ND
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectAccess to care
dc.subjectCorrectional facilities
dc.subjectMedications for opioid use disorder
dc.subjectHealth services research
dc.subjectOpioid use disorder
dc.subjectIncarceration
dc.titlePost-incarceration outcomes of a comprehensive statewide correctional MOUD program: a retrospective cohort study
dc.typeText
dc.type.genreJournal article
dc.description.departmentSocial and Behavioral Sciences
dc.relation.doihttp://dx.doi.org/10.1016/j.lana.2022.100419
dc.ada.noteFor Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu
dc.description.schoolcollegeTemple University. College of Public Health
dc.creator.orcidHoadley|0000-0003-1360-0358
dc.temple.creatorHoadley, Ariel
refterms.dateFOA2024-03-29T19:09:35Z


Files in this item

Thumbnail
Name:
HoadleyEtAl-JournalArticle-202 ...
Size:
279.2Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs CC BY-NC-ND
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs CC BY-NC-ND